Favipiravir (T-705) inhibits in vitro norovirus replication

  • Biochem Biophys Res Commun. 2012 Aug 10;424(4):777-80. doi: 10.1016/j.bbrc.2012.07.034.
J Rocha-Pereira  1 ,  D Jochmans ,  K Dallmeier ,  P Leyssen ,  M S J Nascimento ,  J Neyts
Affiliations
  • 1. Laboratório de Microbiologia, Departamento de Ciências Biológicas, Faculdade de Farmácia, Universidade do Porto, Rua de Jorge Viterbo Ferreira n.° 228, 4050-313 Porto, Portugal.
PMID: 22809499 DOI: 10.1016/j.bbrc.2012.07.034
Abstract

Human noroviruses are the primary cause of foodborne gastroenteritis. Potent and safe inhibitors are needed for the treatment/prophylaxis of norovirus infections. We demonstrate that Favipiravir [T-705, a drug in advanced clinical development for the treatment of infections with the Influenza Virus] inhibits in vitro murine norovirus replication. Time-of-drug addition studies reveal that T-705 exerts its activity at a time-point that coincides with onset of viral RNA synthesis, which is in line with the viral polymerase as the presumed target.

Products